According to new data presented at the EuroPCR conference in Paris, the one-year outcomes of Meril Life Sciences' Myval Transcatheter Aortic Valve Replacement (TAVR) valve are comparable to the popular TAVR platforms from Medtronic and Edwards Lifesciences.

Indian medical technology company Meril Life Sciences has been producing its Myval Transcatheter Heart Valve (THV) for many years. These devicesAlready approved and launched in India and Europe., although they have not yet been approved by the U.S. Food and Drug Administration. Meanwhile, Medtronic's self-expanding Evolut TAVR platform and Edwards Lifesciences' balloon-expandable Sapien 3 TAVR platform are the two most popular treatment options among U.S. cardiologists.

LANDMARKThe clinical trial is a multicenter head-to-head comparison between patients treated with the Myval TAVR valve and those treated with the Evolut or Sapien 3 TAVR valves. It plans to follow up each patient for up to 10 years. Researchers released the 30-day results as early as January, but this specific analysis focuses on the outcomes after one year.

Myval TAVR Valve. Image provided by Meril Life Sciences.

Researchers found that, overall,The one-year survival rates of the two groups of patients were almost the same; the one-year survival rate of the Myval TAVR valve was 92.8%, and the one-year survival rate of the Medtronic/Edwards Lifesciences TAVR valve was 92.9%. Quality of Life (QoL) and hemodynamic parameters were also comparable.

"This trial reflects a new era in comparative valve research," said Patrick Serruys, MD, PhD, Chairman and Principal Investigator of the LANDMARK trial and senior interventional cardiologist at the National University of Ireland, in a statement.EssenceHeartThe design and adherence to the VARC-3 standard (including QoL endpoints) make it a pivotal study. The results of the LANDMARK trial represent a meaningful advancement for the global structural heart disease community.Most importantly, for patients undergoing TAVR, these data not only validate the safety and efficacy of the Myval THV series but also highlight its adaptability to complex anatomical structures. This versatility is precisely what clinicians need to provide precise care for a broad patient population.

"The LANDMARK trial is not only an important milestone for Meril but also a significant milestone for the global TAVR community," added Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril. "The robust results of the year confirm that the Myval THV series is the next-generation solution, delivering consistent safety, clinical efficacy, and improved quality of life across regions. As the only head-to-head trial in its class to include both balloon-expandable and self-expanding valves, it underscores the versatility of the Myval THV series and its practical relevance to diverse patient anatomies and healthcare systems. At Meril, we are proud to contribute innovative, evidence-based technologies that are reshaping patient care and expanding global access to advanced structural heart disease therapies."